Loading
Life sciences · Journal article
Anz Journal of Surgery · October 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Background The PANAMA score was developed as a post‐NAT prognostic tool for PDAC. Prior validations have been dominated by pancreatic head cancers. Pancreatic body and tail tumours represent a biologically distinct subgroup and remain underrepresented in NAT cohorts. Whether the score reliably predicts outcomes in distal PDAC remains unknown. Methods A retrospective study was conducted at a single centre including patients with PDAC who received NAT followed by distal pancreatectomy between January 2015 and December 2024. Patients were stratified into low‐, intermediate‐ and high‐risk groups based on the original PANAMA score. Overall survival (OS) and disease‐free survival (DFS) were assessed. Prognostic performance of the PANAMA score and AJCC staging was compared. Results Fifty‐two patients were included. Median OS and DFS were 40.8 months (95% CI: 28.7–55.0) and 11.6 months (95% CI: 9.7–14.5), respectively. High‐risk patients showed worse OS compared to intermediate‐ and low‐risk groups (21.8, 31.1 and 55.0 months, respectively, p = 0.009). A similar pattern was observed for DFS (10.3, 11.2 and 29.2 months, respectively, p = 0.029). The AJCC stage outperformed the PANAMA score in OS prediction ( C ‐index 0.70 vs. 0.64). Conclusion The PANAMA score effectively stratifies patients with pancreatic body and tail PDACs undergoing neoadjuvant therapy and resection into prognostic groups.